

Kinase Inhibitors from Early Research to Clinic

24th June 2010

**AstraZeneca, Alderley Park Conference Centre,
Alderley Park, Macclesfield**



SMR

Kinase Inhibitors from Early Research to Clinic

Programme:

Protein kinases have become the second most exploited group of drug targets based on the critical role they play in cellular growth, apoptosis and signalling networks. To date, of the nine small molecule approved kinase inhibitors on the market, eight are targeted toward the treatment of oncology indications. Numerous kinases have also been validated as key components for therapeutic intervention in autoimmune, cardiovascular and inflammatory disorders, although the paucity of such inhibitors reaching the market may reflect the increased challenges in delivering safe and selective inhibitors.

This SMR symposium brings together a panel of international speakers across the breadth of research and development in the field of kinase drug discovery, to present and discuss new advances and results from early research to clinical data. Topics include kinase inhibitor design and translating kinase selectivity profiles into early safety guidance, and the discovery and early development of kinase inhibitors in the therapeutic areas of inflammation, pulmonary arterial hypertension, osteoarthritis (OA) induced pain and oncology.

09.00 Arrival, Registration and coffee

09.50 Session 1 - Chair: Andrew Ratcliffe

Kinase research in the 21st century - where is it going?

Prof Andrew Wilks, *SYN|thesis med chem, Australia*

10.45 On the pitfalls of reductionism in today's kinase inhibitor design

Dr Gerhard Mueller, *Proteros Fragments GmbH, Germany*

11.30 Tea

11.50 Small molecule kinase inhibitor promiscuity: Translating kinase selectivity profiles into early safety guidance

Dr Karen Leach, *Pfizer Ltd, USA*



SMR

Kinase Inhibitors from Early Research to Clinic

Programme:

12.35 Lunch

13.45 Session 2 - Chair: Steve Collingwood

JAK inhibitors as novel anti-inflammatory agents

Dr Iain Kilty, *Pfizer, UK*

14.30 Inhibitors of PDGFR kinase as a novel therapy for pulmonary arterial hypertension

Dr Matthew Thomas, *Novartis, UK*

15.15 Tea

15.40 Session 3 - Chair: Jack Allen

Understanding and combating resistance to MEK inhibition

Dr Paul Smith, *AstraZeneca, UK*

16.25 Trk kinase inhibitors - Identification of novel small molecules with potential for cross-therapeutic utility in both oncology and OA-induced pain

Dr Ken Thress, *AstraZeneca, USA*

17.15 Closing remarks and thanks

Future SMR Meetings:

Epigenetics

(Sept, NHLI)

Trends in Medicinal Chemistry

(December, NHLI)



Kinase Inhibitors from Early Research to Clinic

Name:

Address:

Tel: Fax:

Dietary Requirements: Vegetarian: Other:

Registration Fees:

SMR members: £80 Non-Members: £120 Honorary Life Member
Students:* £35 Retired members: £35 (FREE)

Cheque:

If you wish to pay by cheque, then please send your cheque made payable to **Society for Medicines Research**, together with this form to the address given below.

Credit/Debit Card:

To pay by Visa/Eurocard/MasterCard/Switch/Delta/ConnectCard or American Express simply enter your card details below.

Card Nr: Expiry Date:

Please note that deductions will be shown on your statement with the reference

'association enterprises ltd'

Cardholders address if different from above:

Names and addresses of delegates will be included in a list given to all attendees. If you do **NOT** want your name to appear please tick this box.

Fees once paid are not refundable unless a cancellation is received at least 5 working days prior to the event. Delegate substitutes are permitted at any time. Join on-line at www.smr.org.uk or through our secretariat at the address given below.

DATA PROTECTION ACT: By completing and returning this form you agree to allow the Society for Medicines Research to hold and process data about your registration on computer and to pass this information on to 3rd parties as may be required in order to provide the services being offered. The Society for Medicines Research does not rent or sell this data to other companies or organisations.

Society for Medicines Research
840 Melton Road, Thurmaston, Leicester, LE4 8BN, UK
Tel: 0116 2691048, Fax: 0116 264 0141, e-mail: secretariat@smr.org.uk

**Register on-line at:
www.smr.org.uk**